Central Trust Company’s Cytokinetics CYTK Stock Holding History

Central Trust Company’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10	Closed	–	–	1326
2022 Q2	$0	Hold	10	–	–	﹤0.01%	1378
2022 Q1	$0	Buy	+10	New	+$355	﹤0.01%	1371
2021 Q2	–	Sell	-70	Closed	-$2K	–	1196
2021 Q1	$2K	Buy	+70	New	+$1.5K	﹤0.01%	1081

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Central Trust Company's CYTK Position: Q3 2022 in Review

Central Trust Company sold out of Cytokinetics (CYTK) in Q3 2022, closing a stake of 10 shares.

Central Trust Company first reported a position in CYTK in Q1 2021 and held it in 3 quarters. The position peaked at $2K in Q1 2021. 277 funds tracked by Wall St. Rank hold CYTK as of Q3 2022.

Central Trust Company reported no remaining Cytokinetics position as of Q3 2022 after selling out during the quarter.
Central Trust Company sold 10 Cytokinetics shares in Q3 2022.
Central Trust Company first reported a position in Cytokinetics in Q1 2021 and held it in 3 quarters.
Central Trust Company's Cytokinetics position peaked at $2K in Q1 2021.
277 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2022.

Based on Central Trust Company's 13F filing for Q3 2022, filed 3 Nov 2022.